autologous B-cell/monocyte-presenting HER2/neu antigen vaccine BVAC-B

{
  "id": "MLC-T-ONC-011509",
  "term": "autologous B-cell/monocyte-presenting HER2/neu antigen vaccine BVAC-B",
  "field": "Oncology and biomedicine",
  "definition": "An autologous vaccine composed of the antigen presenting cells (APCs) B lymphocytes and monocytes presenting the tumor-associated antigen (TAA) human epidermal growth factor receptor type 2 (HER2/neu; HER-2; EGFR2; ErbB2). Upon administration of the autologous B-cell- and monocyte-presenting HER2/neu antigen vaccine BVAC-B, the APCs may stimulate the immune system to mount a HER2/neu-specific cytotoxic T-lymphocyte (CTL) immune response as well as a natural killer (NK) cell, and antibody-mediated immune response against HER-2/neu-positive tumor cells, which may result in tumor cell death and decreased tumor growth. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF), is overexpressed by a variety of tumors.",
  "synonyms": [
    "HER2/neu-specific autologous B-cell/monocyte vaccine BVAC-B"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-b-cell-monocyte-presenting-her2-neu-antigen-vaccine-bvac-b/"
}